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Virus infection is sensed in the cytoplasm by retinoic
acid-inducible gene I (RIG-I, also known as DDX58),
which requires RNA and polyubiquitin binding to
induce type I interferon (IFN) and activate cellular
innate immunity. We show that the human IFN-induc-
ible oligoadenylate synthetases-like (OASL) protein
has antiviral activity and mediates RIG-I activation
bymimicking polyubiquitin. Loss ofOASL expression
reduced RIG-I signaling and enhanced virus repli-
cation in human cells. Conversely, OASL expression
suppressed replication of a number of viruses in a
RIG-I-dependent manner and enhanced RIG-I-medi-
ated IFN induction. OASL interacted and colocalized
with RIG-I, and through its C-terminal ubiquitin-
like domain specifically enhanced RIG-I signaling.
Bone-marrow-derived macrophages from mice defi-
cient forOasl2 showed that among the twomouse or-
thologs of human OASL, Oasl2 is functionally similar
to human OASL. Our findings show a mechanism by
which human OASL contributes to host antiviral re-
sponses by enhancing RIG-I activation.
INTRODUCTION
Initiation of cellular innate immunity to virus infection is reliant
upon sensing viral nucleic acid in the cytoplasm by the retinoic
acid-inducible gene I (RIG-I)-like receptors (RLR) (Yoneyama
et al., 2004). Upon binding to viral RNA, RIG-I or melanoma dif-
ferentiation-associated gene 5 (MDA5) engage with their com-
mon adaptor mitochondrial antiviral-signaling protein (MAVS)
(Loo and Gale, 2011) on the mitochondrial surface and initiate936 Immunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc.a signal transduction to transcriptionally induce a series of anti-
viral genes including type I interferons (IFNs) (Loo and Gale,
2011; Yan and Chen, 2012). RLR signaling is tightly regulated
by several mechanisms, such as protein expression and post-
translational modifications, to prevent aberrant activation and
IFN production that can be toxic to the cell. Ubiquitination or
deubiquitination of critical RLR pathway components appears
to be one such mode of regulation (Oshiumi et al., 2012).
Although a number of cellular proteins associated with mito-
chondrial function have been found to be important for the
successful signal transduction through this pathway (Moore
and Ting, 2008), host cell factors that function as positive regu-
lators of RIG-I signaling have been less characterized.
A number of structural studies (Civril et al., 2011; Jiang et al.,
2011; Kowalinski et al., 2011; Luo et al., 2011) have indicated a
two-step mechanism for RIG-I activation, involving sequential
binding of 50-triphosphate containing RNA and K63-linked poly-
ubiquitin (pUb) (Zeng et al., 2010). The ubiquitin ligase TRIM25
has been described to be primarily responsible for the second
step of RIG-I activation by ubiquitination or synthesis of short
K63-linked pUb chains (Gack et al., 2007; Zeng et al., 2010).
Another ubiquitin ligase, RNF135 (also known as Riplet), is
similarly involved in the positive regulation of RIG-I signaling,
whereas RNF125 and the deubiquitinase CYLD (Oshiumi et al.,
2012) are known to negatively regulate RIG-I signaling. In
contrast, activation of MDA5 involves the formation of ATP-
sensitive MDA5 filaments along dsRNAs. Because the CARDs
(Caspase activation and recruitment domains) of MDA5 are
accessible and aligned in these filaments, it is believed to lead
to MAVS aggregation along these filaments and TRIM25-inde-
pendent activation of MAVS (Wu et al., 2013).
Type I IFNs exert their pleiotropic effects through the induction
of a variety of IFN-stimulated genes (ISGs) (Sadler and Williams,
2008; Sarkar and Sen, 2004; Yan and Chen, 2012). Although the
antiviral activities for a comprehensive list of ISGs have been
recently described (Schoggins et al., 2011), the mechanism of
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known. Oligoadenylate synthetases (OAS) are a family of ISGs
characterized by their ability to synthesize 20-50 oligoadenylates,
which induce RNA degradation by activating RNaseL (Kristian-
sen et al., 2011). However, the recent identification of the cyto-
plasmic DNA sensor cyclic GMP-AMP synthase (cGAS), which
is another member of OAS family, shows potential diverse func-
tions of these proteins (Sun et al., 2013). Human OASL is related
to the OAS family by its N-terminal OAS-like domain, but lacks
20-50 oligoadenylate synthetase activity because of character-
istic changes in the active site. Furthermore, OASL contains
two tandem ubiquitin-like domains (UBL) in the C terminus,
which are absent in other OAS proteins (Hartmann et al., 1998;
Rebouillat et al., 1998). OASL is rapidly induced by virus infection
via interferon regulatory factor 3 (IRF3) as well as by IFN signaling
(Melchjorsen et al., 2009; Sarkar and Sen, 2004) and has been
shown to have antiviral activities, which requires the UBL domain
(Marques et al., 2008; Schoggins et al., 2011). However, in
the absence of the catalytic activity, the mechanism of human
OASL antiviral activity has remained elusive.
Here we describe a role for human OASL in enhancing RIG-I-
mediated signaling through its UBL and define a mechanism by
which OASL induces viral resistance. Genetic targeting of OASL
in human cells, as well as in mouse macrophages derived from
Oasl2/ mice, reduced RIG-I activity, resulting in enhanced
virus replication. We propose a model whereby OASL, induced
after virus infection, directly binds to RIG-I and mimics pUb in
order to sensitize its activation by viral RNA, thus enhancing
antiviral signaling.
RESULTS
Unlike Mouse Oasl1, Human OASL Does Not Bind IRF7
mRNA and Instead Exhibits Antiviral Activity
The humanOASLwas discovered as a member of theOAS fam-
ily genes from the EST database (Hartmann et al., 1998; Rebouil-
lat et al., 1998). Subsequently, two orthologs were identified
in mouse chromosome 5 and termed Oasl1 and Oasl2 with
70% and 48%, respectively, amino acid sequence identity with
human OASL (Eskildsen et al., 2003). A pseudogene, named
JhOASL2 has been found adjacent to human OASL with partial
homology to the mouse Oasl2 gene, but contains only the first
two exons and lacks protein-coding ability (Figure S1A available
online; Eskildsen et al., 2003).
Human OASL protein has been reported to provide antiviral
activity against RNA viruses (Marques et al., 2008; Schoggins
et al., 2011). However, the mouse ortholog of human OASL,
Oasl1, has been recently shown to inhibit IFN induction by bind-
ing to the 50 UTR of IRF7 and inhibiting its translation. Conse-
quently, targeted deletion ofOasl1 led to enhanced IFN induction
and diminished viral replication in vivo (Lee et al., 2013). To deter-
mine whether human OASL is capable of binding to the IRF7
50 UTR, we used a RNA pull-down assay (Figure 1A). 30-biotin-
labeled RNA corresponding to the 50 UTR of human or mouse
IRF7 was incubated with purified V5-tagged human or mouse
OASL proteins in various combinations, and the complexes
were precipitatedwith Streptavidin-agarose beads and analyzed
by immunoblotting with V5 antibody. As observed before, mouse
Oasl1 strongly bound to the 50 UTR of mouse IRF7 (Figure 1A,lane 11), but less strongly to the 50 UTRof human IRF7 (Figure 1A,
lane 9). However, we did not detect appreciable binding of
human OASL to either human or mouse IRF7 50 UTR (Figure 1A,
lanes 5–8). The binding specificity of each protein was demon-
strated by competition with 8-fold molar excess of correspond-
ing unlabelled RNA. These results indicate that unlike mouse,
human OASL does not bind to the IRF7 50 UTR to inhibit its trans-
lation and may exert unique biological activities.
To further examine the antiviral function of human OASL, we
generated OASL-deficient 293T cells (293T-OASL/) through
TALEN-mediated genome editing (Schmid-Burgk et al., 2013).
In contrast to mouse Oasl1/ cells, which exhibited enhanced
IRF7 induction, human OASL/ cells showed a severe
reduction in IRF7 induction upon activation of RLR signaling
by low-molecular-weight poly(I:C) (LMW) transfection (Fig-
ure 1B). Further, human 293T-OASL/ cells showed enhanced
viral replication when infectedwith various RNA viruses including
vesicular stomatitis virus (VSV), respiratory syncytial virus (RSV),
and Sendai virus (SeV) (Figures 1C–1F).We validated the antiviral
role of OASL by silencing OASL expression with siRNA in primary
human fibroblasts and keratinocytes by siRNA and observed
enhanced SeV replication (Figure 1G). Taken together, these
results indicated unique antiviral functions for human OASL
compared to themouseOasl1, which was found to enhance viral
replication.
OASL Expression Leads to Resistance to Infection by a
Number of DNA and RNA Viruses
As a typical ISG, OASL protein is not expressed in naive cells. To
further clarify these apparent contradictory functions of human
OASL andmouseOasl1, we used stable expression of V5-tagged
human OASL in various cell lines and examined their antiviral
activity against a broad range of viruses. The physiologically rele-
vant amount of ectopic OASL expression was confirmed by
comparing the amount of exogenous OASL expression with that
of endogenous OASL induction after IFN treatment (Figure S1B).
OASL-expressing HT1080 cells infected with VSV exhibited
lower levels of viral replication (as measured by GFP fluores-
cence) compared to HT1080-Vector cells (Figure 2A). Similarly,
HEK293-OASL cells showed reduced VSV replication by immu-
noblotting (Figure 2B) and plaque assay (Figure 2C). SeV infection
of these cells showed reduced SeV RNA (Figure S1C) and C pro-
tein (Figure 2D). Markedly reduced virus replication in HEK293-
OASL cells was observed with RSV (Figure 2E) and dengue virus
type 2 (DENV) (Figure 2F), indicating antiviral activity of human
OASL.Weexamined the antiviral activity of OASLagainst the her-
pes simplex virus-1 (HSV-1) and observed reduced virus produc-
tion in HEK293-OASL cells (Figure 2G). However, OASL did not
provide protection against encephalomyocarditis virus (EMCV)
(Figure S1D). Furthermore, siRNA-mediated silencing of OASL
did not enhance EMCV replication in primary human keratino-
cytes (Figure S1E) or fibroblasts (Figure S1F). These results
show that unlike mouse Oasl1, human OASL provides antiviral
activity against specific RNA and DNA viruses.
Antiviral Activity of OASL Is Reduced in the Absence
of RIG-I
RIG-I is the primary sensor of viral RNA for VSV, SeV, and
RSV infection (Loo and Gale, 2011). In conjunction with RNAImmunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc. 937
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Figure 1. Unlike Mouse Oasl1, Human OASL Does Not Bind IRF7 mRNA, and Its Loss Enhances Replication of a Number of RNA Viruses
(A) Comparison between human and mouse IRF7 50 UTR binding to human OASL or mouse Oasl1 proteins. Biotin-labeled IRF7 50 UTR RNA were incubated with
the partially purified V5-tagged OASL or Oasl proteins and pulled down by streptavidin beads. After extensive wash, bead-bound proteins were analyzed by
immunoblotting (IB) with V5 antibody.
(B) Reduced IRF7 induction in 293T-OASL/ cells. 293T-OASL/ and control 293T cells were transfected with LMW for 24 hr and analyzed by IB. NS indicates
nonspecific.
(C and D) VSV replication in 293T-OASL/ cells detected by IB using anti-GFP antibody (C) or by plaque assay (D) 24 hr postinfection.
(E) RSV replication in 293T-OASL/ cells. Cells were infected with RSV at 3 m.o.i. for 18 hr followed by total RNA extraction and detection by qRT-PCR.
(F) SeV replication in 293T-OASL/ cells detected by IB using SeV C protein antibody 24 hr after infection. Densitometric analysis of the immunoblot is shown
below.
(G) OASL silencing results in higher SeV replication in primary human cells. Primary human foreskin fibroblasts or keratinocytes were transfected with
lipofectamine RNAiMAXwith either 50 nMOASL siRNA or control siRNA (ON-TARGETplus, SMARTpool, Thermo Scientific) for 48 hr. The cells were then infected
with SeV at indicated doses for another 24 hr followed by detection of SeV-specific RNA by qRT-PCR.
Plots show mean with standard error bars, where closed diamond set as 1 for comparison.
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HEK293 cells (Ablasser et al., 2009; Chiu et al., 2009). In contrast,
MDA5 has been implicated in the sensing of picornaviruses such
as EMCV (Kato et al., 2006; Loo and Gale, 2011). Because OASL
showed antiviral activity against VSV, SeV, RSV, and HSV-1, but
not EMCV, we examined the dependence of this antiviral activity
on RIG-I by three approaches: (1) transient silencing of RIG-I in
HEK293 vector or OASL stable cells by siRNA; (2) establishment
of an OASL-expressing HEK293 stable cell line where RIG-I has
been partially silenced by shRNA expression; and (3) expression
of OASL in RIG-I-deficient 293T cells (293T-DDX58/). As ex-
pected, targeting of RIG-I increased VSV replication (assessed
by quantitation of VSV RNA by qRT-PCR [Figure 3A], immuno-
blotting with anti-GFP [Figure 3C, lanes 2 and 4]), whereas938 Immunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc.OASL expression reduced VSV replication (Figures 3A and 3C,
lanes 4 and 8). However, in the absence of RIG-I, there was no
antiviral activity of OASL (Figures 3A and 3C, lanes 2 and 6).
The steady-state levels of RIG-I mRNA are shown in Figures
3B and 3D, demonstrating more than 50% reduction of RIG-I
mRNA with siRNA or shRNA targeted to RIG-I. In parallel, we
expressed OASL in 293T-DDX58/ and 293T cells. OASL-ex-
pressing 293T cells inhibited VSV replication (Figure 3E, lanes
3 and 4), whereas OASL-expressing 293T-DDX58/ cells did
not (Figure 2E, lanes 1 and 2; Figure 3F). Because RIG-I is the
primary sensor for VSV, IFN and ISG induction by VSV infection
is mostly absent in the RIG-I-null cells. However, to exclude
the possible role of any residual ISG induced in 293T-DDX58/
cells via IFN receptor (IFNAR) signaling, we silenced IFNAR1
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Figure 2. OASL Expression Provides Cellular Antiviral Activity
(A) OASL expression inhibits VSV infection. Cells were infected with VSV-GFP at 1 m.o.i. GFP florescence was observed under florescence microscope 8 hr after
infection. Representative micrograph from at least three separate experiments is shown.
(B and C) Expression of OASL reduces VSV replication. Cells were infected with VSV-GFP at the indicated m.o.i. for 8 hr followed by IB using GFP antibody (B).
Supernatants from similarly infected cells (5 m.o.i.) were used for plaque assay on BHK21 cells (C).
(D) OASL expression inhibits SeV infection. SeV-infected (24 hr) cells were analyzed by IB using antibody against SeV C protein. Densitometric analysis of the
protein bands are shown below.
(E–G) OASL expression inhibits RSV, DENV, and HSV-1 replication. Cells were infected with RSV (3 m.o.i.) for 48 hr, followed by plaque assay on Hep2 cells (E).
Cells were infected with type 2 dengue virus (DENV) at indicated doses for 48 hr followed by qRT-PCR for DENV-specific RNA (F). Cells were infected with HSV-1
at 5 m.o.i. for 24 hr followed by plaque assay on Vero cells (G).
Plots show mean with standard error bars, where closed diamond set as 1 for comparison.
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functional reduction of IFN signaling indicated by the reduced
ISG60 induction (Figure S1G, lanes 5–8), VSV replication in
293T-DDX58/ cells remained unaffected by OASL either in
the presence or absence of IFNAR signaling (Figure S1G, lanes
1–4). Results from the above experiments indicate that OASL-
mediated antiviral activity against VSV is dependent on RIG-I.
Expression of OASL Enhances Sensitivity of RIG-I
Signaling
RIG-I initiates downstream signaling through its adaptor MAVS
and induce transcription of type I IFNs and ISGs. Because
OASL antiviral activity was dependent on RIG-I, in the next series
of experiments we tested whether OASLmodulated gene induc-
tion via the RIG-I pathway. OASL led to a substantial enhance-
ment of IFN-b and ISG56 promoter activity at various doses
of SeV, whereas another OAS family member, OAS1, did not
(Figures 4A and S2A). Similarly, OASL-expressing HEK293 or
HT1080 cells demonstrated higher levels of endogenous
ISG56, ISG60, and IFN induction after SeV infection, or RIG-I-
specific LMW transfection, indicating enhanced RIG-I pathway
activation in the presence of OASL (Figures 4B, 4C, S2B, and
S2C). Early events of RIG-I signaling, such as IRF3 dimerization
(Figure 4D) and nuclear translocation (Figure 4E), were also
enhanced in the presence of OASL. Induction of RIG-I-mediated
NF-kB-regulated genes was also enhanced in OASL-expressingcells (Figure 4F). The presence of OASL did not alter the kinetics
of RIG-I-mediated ISG induction, but the magnitude was sub-
stantially enhanced (Figure S2D). To further understand the na-
ture of this enhancement in RIG-I signaling by OASL, we created
HT1080 cell line with doxycycline-inducible OASL expression
(HT1080-iOASL) and infected them with subthreshold doses
of SeV (2 HAU/ml, 8 hr). As shown in Figure 4G, there was no
detectable ISG60 induction in response to this subthreshold
SeV infection in cells (Figure 4G, lane 2). However, upon doxycy-
cline treatment, ISG60 was upregulated in an OASL expression-
dependent manner. Taken together, these results indicate that
OASL expression enhances viral RNA-induced RIG-I signaling
and that the increases in IFN and ISG induction in the presence
of OASL are due to enhanced sensitivity of the RIG-I pathway,
not to changes in the kinetics of induction.
The UBL domain of OASL has been implicated in its antiviral
activity (Marques et al., 2008). We confirmed the contribution
of the UBL in enhancing RIG-I signaling in cell lines expressing
UBL-deleted OASL (OASLDUBL). Cells expressing OASLD1D2
were not protected from VSV infection (Figure S2E) and did not
show enhanced induction of IFN-b, ISG56, and ISG60 mRNA
(Figures 4H, S2F, and S2G) and proteins (Figure 4I) with SeV.
However, expression of the UBL of OASL alone did not cause
enhancement of RIG-I signaling (Figure S2H). These results
indicate that the OASL UBL is necessary, but not sufficient, to
enhance RIG-I signaling.Immunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc. 939
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Figure 3. OASL Antiviral Activity Is Dependent on RIG-I
(A and B) Loss of RIG-I expression reduces OASL antiviral activity against VSV. Cells were transfected with 50 nM RIG-I or control siRNA (Dharmacon) for 48 hr,
followed by VSV infection (1m.o.i., 24 hr). Total RNA from the infected cells were extracted and analyzed for VSV replication (A) and RIG-I mRNA (B) by qRT-PCR.
(C) Indicated cells were transfected with psiRNA-Ctrl or psiRNA-hRIG-I plasmids (Invivogene) followed by Zeocin selection. VSV-infected (1 m.o.i.) cells were
immunoblotted with indicated antibodies.
(D) Levels of RIG-I silencing were estimated by qRT-PCR.
(E and F) Expression of OASL in RIG-I-null cells does not protect them from VSV. OASL-expressing 293T-DDX58/ and control cells were infected with 1 m.o.i.
VSV for 24 hr followed by IB with indicated antibodies (E) and qRT-PCR to detect VSV replication (F).
Plots show mean with standard error bars, where closed diamond set as 1 for comparison.
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Enhances Virus Replication
Next, we investigated the involvement of OASL in RIG-I signaling
by ablating OASL expression in different systems. We tested
various cell lines and found that the colon cancer cell line HCT-
116 showed detectable, albeit low, basal OASL expression,
that was strongly induced by SeV infection or IFN-a treatment
(Figures S3A and S3B). Multiple shRNAs targeting OASL were
used to establish stable cell lines (HCT-116 and HEK293)
in which basal and SeV or dsRNA-inducible endogenous OASL
expression was partially ablated (Figure 5A, panel 3, and Figures
S3C and S3F). Upon SeV infection or LMW transfection of
these cells, ISG60, ISG56, and IFN induction was substantially
reduced compared to control (Figure 5A, panels 1 and 2; Figures
5B, 5C, and S3D–S3F). Consequently, loss of OASL in HCT-116-
shOASL cells substantially increased VSV and SeV replication
(Figures S3G and S3H). For further validation, homozygous short
deletions in the genomic OASL locus were introduced using
TALENs. The resulting HCT-116-OASL/ and 293T-OASL/
cells showed reduced RIG-I signaling as measured by ISG
induction (Figures 5D–5F, lanes 4–6). As expected, the control
293T-DDX58/ cells also showed complete loss of ISG induc-
tion (Figure 5F, lanes 7–9). In addition, confirming the role of
OASL in RIG-I-mediated NF-kB activation, 293T-OASL/ cells
also showed diminished NF-kB-regulated gene induction (Fig-
ure 5G). Similar results were obtained in primary human keratino-
cytes upon OASL silencing by siRNA (Figures 5H and 5I). Taken
together, these results confirm the positive role of human OASL
in RIG-I signaling and antiviral responses.940 Immunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc.Genetic Depletion of Mouse Oasl2 Reduces RIG-I
Signaling and Enhances Virus Replication
Because mouse Oasl1 did not share the antiviral properties of
human OASL, we examined the properties of mouse Oasl2 and
tested their comparative binding abilities to the 50 UTR regions
of IRF7 mRNA. In a similar experiment to Figure 1A, human
OASL and mouse Oasl2 did not bind to human or mouse IRF7 50
UTR (Figure S3I, lanes 15–18). Next, we compared their effects
on RIG-I signaling by using isoform-specific shRNA in mouse
embryonic fibroblasts (MEFs). Specific silencing was validated
by measuring the loss of SeV-induced induction of either Oasl1
or Oasl2 mRNA (Figure S3J, bottom). In the same experiment,
silencing of Oasl2 partially reduced SeV-mediated IFN-b (Ifnb1)
and Isg56 (Ifit1) mRNA induction, indicating that mouse Oasl2
mightbe functionallyequivalent tohumanOASL. Toconfirmthese
results and provide evidence for the antiviral activity of Oasl2
in vivo,weusedOasl2-deficientmice. Thesemiceweregenerated
by inserting agene trapping cassette in theOasl2 locus,where the
third exon was spliced into a LacZ cassette, thus abrogating
the expression of the endogenous locus (Figures S3K and S3L),
and the same resource had been successfully used to define
cGAS-deficient mice phenotype (Li et al., 2013; Schoggins
et al., 2014). Bone-marrow-derived macrophages (BMDMs)
from Oasl2/ mice showed expected loss of Oasl2 expression
compared to wild-type upon SeV infection (Figure S3M). Subse-
quent analysis of Ifnb1 and Ifit1 mRNA induction by SeV also
showed substantial reduction in Oasl2/ BMDMs (Figures 5J
and 5K), which were further corroborated by analyzing mouse
IFN-b protein by ELISA (Figure 5L). Finally, the Oasl2/
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Figure 4. OASL Enhances RIG-I Signaling
(A) OASL expression enhances IFN-b-reporter activity. HEK293 cells were cotransfected either with control pcDNA3 (1), pcDNA3-OAS1 (2), or pcDNA3-OASL (3)
in combination with IFN-b-luciferase reporter and b-actin Renilla luciferase reporter for 24 hr. One part of the transfected cells was used for IB to detect protein
expression (inset) and the other part was stimulated with SeV for 16 hr and luciferase activities were measured.
(B and C) OASL expression enhances RIG-I signaling. Cells were infected with SeV for 16 hr followed by IB using ISG56, ISG60, V5 (OASL), and actin antibodies
(B). Cells were transfected with LMW for 24 hr followed by IB with indicated antibodies (C).
(D and E) IRF3 dimerization and nuclear localization is enhanced in OASL-expressing cells. Indicated cells were stimulated with SeV for 12 hr. Cell lysates were
analyzed in native-PAGE followed by IB with IRF3 antibody (D). Nuclear extracts (NE) from similarly stimulated cells were analyzed along with control uninfected
cytoplasm (CP) by IB for IRF3 and nuclear marker DRBP76, respectively (E).
(F) NF-kB-dependent gene inductions are also enhanced in OASL-expressing cells. Indicated cells were either transfected with LMW or infected with SeV for
24 hr followed by qRT-PCR analysis with indicated primers to detect NF-kB-controlled gene induction.
(G) Dose-dependent enhancement of RIG-I-signaling sensitivity by OASL. HT1080-iOASL cells were stimulated with doxycycline at indicated concentrations for
48 hr followed by infection with SeV (2 HAU/ml) for 8 hr. Cell lysates were analyzed by IB as indicated.
(H) UBL-deleted OASL mutant does not enhance SeV-mediated IFN-b induction. Cells were either mock infected or infected with 20 HAU/ml SeV for 16 hr. Total
RNA from each well were extracted followed by qRT-PCR using IFN-b-specific primers.
(I) OASL-mediated enhancement of ISG induction by SeV is dependent on its UBL. Various OASL-expressingHT1080 cells were infectedwith SeV as indicated for
16 hr followed by IB with indicated antibodies as before.
Plots show mean with standard error bars.
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cation compared to wild-type (WT), establishing the antiviral role
mouse Oasl2, which was similar to human OASL (Figure 5M).
These results suggest that mouse Oasl2 is functionally similar to
human OASL and exerts a positive role in antiviral signaling.
OASL Specifically Activates RIG-I Signaling Upstream of
MAVS
To understand the molecular mechanism and the possible stage
at which OASL regulated RIG-I pathway, we overexpressed
components of RLR signaling and assessed the effects ofOASL expression. 293T-DDX58/ cells were used to avoid
any feed-forward effect from RIG-I on resulting ISG induction.
As expected, transient overexpression of MAVS and constitu-
tively active IRF3-5D caused ISG56 induction in 293T-DDX58/
cells, indicating the activation of the RLR signaling downstream
of RIG-I (Figures 6A and 6B, lanes 1–3). However, the presence
of OASL did not affect ISG56 induction in these conditions
(Figures 6A and 6B, lanes 4–6), indicating that OASL affected
the RLR signaling upstream of MAVS. To further define the
RIG-I-specific activity of OASL, we tested the effect of OASL
on MDA5 signaling by using both OASL-expressing andImmunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc. 941
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Figure 5. Loss of Human OASL and Mouse Oasl2 Reduces RIG-I Signaling and Enhances Virus Replication
(A–C) Inhibition of RIG-I signaling in HCT-116 cells after OASL silencing. HCT-116 cells stably expressing OASL shRNA (two different shRNA, sh1-OASL and sh2-
OASL, targeting two different regions of OASL mRNA) or control vector stimulated with SeV as indicated for 24 hr followed by IB with indicated antibodies (A).
Indicated cells were stimulated with SeV as in (A), and the cellular RNA were analyzed for IFN-amRNA by qRT-PCR (B). Same HCT-116 OASL shRNA and control
cells were transfected with LMW for 24 hr followed by IB with the indicated antibodies (C).
(D and E) Reduction of RIG-I-mediated ISG induction in HCT-116-OASL/ cells. OASL/ HCT-116 and wild-type HCT-116 cells were either infected with SeV
(D) or transfected with LMW (E) as indicated, followed by IB for ISG60, OASL, and actin antibodies, respectively.
(legend continued on next page)
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pression was not affected by the presence of OASL at two
different doses (Figure 6C). Similarly, induction of either ISG60
or IRF7 by constitutively active MDA5 CARD (MDA5(N)) was
not affected in 293T-OASL/ cells compared to 293T cells
(Figure 6D). OASL silencing had no effect on EMCV-mediated
induction of IFN-b in human primary keratinocytes (Figure 6E).
It has been demonstrated that transfection of replicating viral
RNA into U2OS cells prepared from EMCV-infected 293T cells
induces IFN-b in a MDA5-dependent manner, whereas that
from SeV- or VSV-infected cells activates RIG-I signaling (Jiang
et al., 2012). We verified the ISG induction by replicating EMCV
viral RNA in U2OS cells (Figure S4A) and tested the effect
of OASL silencing on ISG induction. As shown in Figure 6F,
ISG60 and IRF7 induction by RNA prepared from SeV-infected
cells was reduced by OASL silencing (lanes 2 and 5) whereas
that using RNA fromEMCV-infected cells was not affected (lanes
3 and 6). Taken together, these results indicated that OASL
specifically enhanced RIG-I signaling upstream of MAVS.
OASL Specifically Binds and Colocalizes with RIG-I
To understand the biochemical mechanism of RIG-I signaling
enhancement by OASL, we investigated their interaction. V5-
tagged OASL was coexpressed with FLAG-tagged RIG-I in
HEK293 cells (schematic, Figure S4B). Immunoprecipitation
with FLAG antibody showed that OASL coprecipitated with
RIG-I, although another OAS family member, OAS1, did not (Fig-
ure 6G). Additionally, UBL-deleted OASL (OASLDUBL) also in-
teracted with RIG-I, indicating that the OAS domain of OASL is
sufficient to mediate RIG-I interaction (Figure 6G). To map the
interaction domain in RIG-I, we used various RIG-I mutants
with deleted domains (schematic, Figure S4B). Surprisingly,
both N-terminal CARD-deleted (RIG-I(C)) and helicase plus
C-terminal domain (CTD)-deleted RIG-I (RIG-I(N)) interacted
with OASL (Figure 6H), indicating that both domains of RIG-I
interact with full-length OASL. However, when the C-terminal
domain of RIG-I (RIG-I(CTD)) was coexpressed with either
OASLDUBL or OAS1, only the OAS-like domain of OASL
(OASLDUBL) specifically interacted with RIG-I(CTD) (Figure 6I).
This showed that theOAS-like domain of OASL specifically inter-
acted with the CTD of RIG-I, allowing further interaction of RIG-I
CARDs with OASL, presumably with the UBL (see below). To un-
derstand the biochemical basis of OASL to specifically enhance
RIG-I and notMDA5 signaling, we compared interaction of OASL
with RIG-I and MDA5 CARDs. As shown in Figure 6J, RIG-I(N),
not MDA5(N), specifically coimmunoprecipitated with OASL.(F) ISG induction in OASL- and RIG-I-targeted 293T cells. Wild-type 293T, 293
followed by IB for the indicated proteins.
(G) Effect of OASL loss on RIG-I-mediated induction of NF-kB target genes. Ce
NF-kB-regulated genes.
(H and I) OASL silencing reduces ISG60 induction by RIG-I signaling in primary hu
control siRNA for 48 hr, followed by either transfection with LMW or infection wi
(J and K) Downregulation of RIG-I-mediated Ifnb1 (IFN-b) and Ifit1 (ISG56) mRNA
mice were infected with SeV for 8 hr followed by detection of Ifnb1 (J) and Ifit1 (K
(L) Secreted IFN-b was measured in the supernatants from SeV-infected (8 hr)
ELISA kit.
(M) Increased VSV replication in BMDMs fromOasl2/mice. BMDMs fromWT or
RNA by qRT-PCR.
Plots show mean with standard error bars, where closed diamond set as 1 for cFurthermore, in an in vitro binding assay by purified RIG-I(N) or
MDA5(N) and OASL or OAS1, we found that it is only RIG-I(N)
that specifically bound to OASL (Figure 6K). Endogenous
OASL and RIG-I showed interaction in coimmunoprecipitation
studies in HEK293 cells (Figure 6L) and primary human fibro-
blasts (Figure 6M). Because of the undetectable levels of OASL
in unstimulated cells, we infected cells with SeV (100 HAU/ml)
to induce OASL expression. As shown in Figures 6L and 6M,
endogenous RIG-I coprecipitated with endogenous OASL. The
specificity of this interaction was demonstrated by testing
OASL-MAVS coprecipitation, which was negative irrespective
of the presence of RIG-I (Figure S4C). To examine the ligand
or virus infection dependence of RIG-I and OASL interaction,
we infected HEK293 cells coexpressing RIG-I and OASL with
different amounts of SeV and immunoprecipitated RIG-I with
anti-FLAG. As shown in Figure S4D, RIG-I-OASL interaction
was detected even in the absence of SeV infection, indicating
that this interaction was not dependent on the presence of
viral RNA.
Finally, to establish the physiological relevance of the RIG-I-
OASL interaction and to examine whether these proteins exist
within the same cellular compartments, we performed immuno-
fluorescence microscopy for endogenous RIG-I and ectopically
expressed OASL in uninfected and SeV-infected HT1080
cells. In uninfected cells, both RIG-I and OASL exhibited diffuse
staining throughout the cytoplasm (Figure 6N, top). However,
upon infection with SeV, RIG-I and OASL translocated to
discrete punctae localized throughout the cytoplasm (Figure 6N,
bottom). RNA virus infection has been shown to translocate
RIG-I to stress granules appearing as discrete punctae (Ono-
moto et al., 2012). We found that OASL was relocalized to stress
granules in response to SeV infection, and not in mitochondria,
as confirmed by its colocalization with a GFP-tagged marker
protein for stress granules, G3BP (Figures S4E and S4F). Taken
together, our results show that OASL interacts with RIG-I to posi-
tively modulate its function and relocalizes to RIG-I-containing
stress granules in response to specific virus infection.
OASL Specifically Enhances RIG-I Signaling by
Mimicking Polyubiquitin
RIG-I is K63 ubiquitinated in its CARDs by the ubiquitin ligases
TRIM25 and Riplet, which is essential for its activation (Gack
et al., 2007; Oshiumi et al., 2012). However, K63-linked pUb
chains synthesized by TRIM25 are sufficient for the complete
activation of RIG-I signaling upon ligand binding (Zeng et al.,
2010). Two mutations in the RIG-I CARD, T55I and K172R,T-OASL/, and 293T-DDX58/ cells were transfected with LMW for 24 hr,
lls were treated similarly as in (F) followed by qRT-PCR analysis of indicated
man keratinocytes. Primary keratinocytes were transfected either with OASL or
th SeV at the indicated doses for another 24 hr and analysis by IB.
induction in Oasl2/ macrophages. BMDMs from wild-type (WT) or Oasl2/
) mRNA by qRT-PCR.
WT (closed circle) and Oasl2/ (open circle) BMDMs via the mouse IFN-b
Oasl2/mice were infected with VSV for 24 hr followed by quantitation of VSV
omparison.
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thereby rendering it inactive. Because of the presence of UBL
and its specific interaction with RIG-I, we hypothesized that
the UBL of OASL might interact with RIG-I and mimic the K63-
linked pUb to activate RIG-I. To test this, we created full-length
and RIG-I(N) carrying T55I and K172R mutations and measured
their OASL binding and signaling abilities with or without OASL.
In coimmunoprecipitation assay, all the mutants and wild-type
RIG-I bound to OASL with equal efficiencies (Figure S5A).
Expression of wild-type RIG-I in HEK293 cells caused ISG60
induction and IFN-b reporter activation that was enhanced by
OASL expression (Figure 7A, lanes 1 and 5; Figure S5B). As ex-
pected, both the T55I and K172R mutants of RIG-I were inactive
when expressed in HEK293-Vector cells (Figure 7A, lanes 2 and
3; Figure S5B). However, when the same mutants were ex-
pressed in HEK293 cells expressing OASL, they were functional
and induced near-wild-type amounts of ISG60 and IFN-b re-
porter activity (Figure 7A, lanes 6 and 7; Figure S5B). Similar re-
sults were obtained for the K172Rmutant in the RIG-I(N) context
(Figure S5C). Thus, OASL expression rescued RIG-I mutants that
failed to interact with K63-linked pUb and are thus defective in
signaling. To provide additional evidence, we silenced TRIM25
expression by siRNA. Reduction of TRIM25 expression caused
inhibition of SeV-mediated ISG60 induction in HEK293-Vector
cells (Figure 7B, lanes 1–3 and 7–9). In contrast, silencing of
TRIM25 had no effect on ISG60 induction in OASL-expressing
cells (Figure 7B, lanes 4–6 and 10–12). Recently, it has been
shown that after long (%112 bp) RNA binding, full-length RIG-I
can be activated in vitro without pUb by ATP-dependent oligo-
merization (Patel et al., 2013; Peisley et al., 2011). However,
pUb binding is necessary for RNA-independent oligomerization
of RIG-I(N) and with full-length RIG-I and short dsRNA (<60 bp)
indicating synergistic parallel mechanisms (Peisley et al.,
2011). To investigate how OASL affect RIG-I oligomerization,Figure 6. OASL Binds to and Specifically Enhances RIG-I Signaling
(A and B) OASL does not affect RLR signaling downstream of MAVS. 293T-DD
indicated plasmids to express either MAVS (A) or constitutively active IRF3-5D (B
(C) OASL does not enhance MDA5 signaling. Cells were transfected either w
followed by IB.
(D) Loss of OASL expression does not affect MDA5 signaling. Cells were transfec
(E) OASL silencing does not affect IFN-b induction stimulated by EMCV infectio
OASL siRNA and control siRNA for 48 hr, followed by EMCV infection for anot
replication (Figure S1E) were analyzed by specific qRT-PCR.
(F) OASL does not affect the gene ISG60 and IRF7 induction triggered by a physiol
or mock infected (Ctrl.) and extracted for total RNA as described before (Jiang e
described in Figure 1 for 48 hr followed by transfection with 1 mg of total RNA pr
(G) RIG-I interacts with OASL. 293T cells were cotransfected for 24 hr with FLA
cipitated (IP) with FLAG antibody, followed by IB with V5 antibody. Whole-cell extr
(H) Both N-terminal CARD and C-terminal Helicase-CTD domains of RIG-I intera
cotransfected as before with indicated plasmids followed by IP analysis.
(I) OAS domain of OASL interacts with RIG-I CTD domain. 293T cells were trans
(J) RIG-I CARD domain (RIG-I(N)) specifically interacts with OASL, whereas MDA
followed by IP analysis.
(K) Specific in vitro interaction of RIG-I(N) with OASL. GST-RIG-I(N) and GST-MD
(His)6-OASL or with (His)6-OAS1 purified from insect cells followed by Ni-NTA pu
(L) Interaction of endogenous OASL and RIG-I. HEK293 cells were infected with
OASL antibody or control IgG followed by IB with RIG-I antibody. Control WCE w
(M) Interaction of endogenous RIG-I and OASL in primary human fibroblasts. Hum
12 and 24 hr, respectively, followed by IP analysis as indicated.
(N) OASL colocalizes with RIG-I in virus-infected cells. HT1080-OASL cells were
with RIG-I and V5 antibodies followed by confocal microscopy. The arrows denowe used purified RIG-I(N) at two different protein concentrations
and compared its oligomerization in the presence or absence of
pUb and OASL via native gel electrophoresis (Patel et al., 2013).
As shown in Figure 7C, both 50 and 100 ng RIG-I(N) showed
monomeric and oligomeric complexes in the absence of RNA
or ATP (lanes 1 and 2). However, with 100 ng RIG-I, the oligo-
meric fraction was increased by pUb as well as by OASL (lanes
4 and 6). In a similar experiment, oligomeric fraction for MDA5(N)
was affected neither by pUb nor by OASL (Figure S5D). This
suggested that OASL binding to RIG-I may help RIG-I-CARD
oligomerization, possibly through its C-terminal UBL, which is
required for MAVS binding and signal propagation.
DISCUSSION
We described a mechanism explaining the antiviral activity of
human OASL whereby OASL bound to RIG-I and specifically
enhanced RIG-I-mediated antiviral signaling. We showed that
similar to human OASL, mouse Oasl2 had antiviral activity and
loss of these proteins resulted in reduced IFN signaling and
enhanced RNA virus replication. Very recently, Lee et al. (2013)
has reported that mouseOasl1 binds to the IRF7 50 UTR to inhibit
its translation, thereby downregulating IFN induction and
enhancing viral replication. However, human OASL has been re-
ported to have antiviral properties (Marques et al., 2008; Schog-
gins et al., 2011). Furthermore, SNP in human OASL has been
linked to altered susceptibility to hepatitis C and West Nile virus
infection (Li et al., 2008; Yakub et al., 2005). Here, using human
cells either with targetedOASL deletion or ectopic OASL expres-
sion, and Oasl2/ macrophages, we established the antiviral
property of OASL and provide a mechanistic model consistent
with previous observation. In contrast to mouse Oasl1, human
OASL and mouse Oasl2 did not bind to human and mouse
IRF7 50 UTR, and neither did humanOASL suppress IRF7 proteinX58/ cells stably expressing OASL or vector control were transfected with
) for 24 hr followed by immunoblot analysis.
ith vector or two different concentrations of FLAG-MDA5 plasmid for 24 hr
ted for 24 hr with indicated amounts of MDA5(N) plasmid and analyzed by IB.
n in keratinocytes. Primary human keratinocytes were transfected with 50 nM
her 24 hr. The OASL silencing (Figure S1E), IFN-b production (E), and EMCV
ogical MDA5 agonist. 293T cells were infected either with EMCV, VSV, and SeV
t al., 2012). U2OS cells were first transfected with control or OASL siRNA as
epared from infected cells as indicated. Cell lysates were analyzed by IB.
G-RIG-I and OASL-V5, OASL-DUBL-V5, or OAS1-V5 plasmids, immunopre-
acts (WCE) from transfected cells were similarly analyzed for expression levels.
ct with OASL. 293T cells were either individually transfected with OASL-V5 or
fected as indicated, followed by similar IP analysis.
5 CARD domain (MDA5(N)) does not. 293T cells were transfected as indicated
A5(N) proteins purified from bacteria were incubated on ice as indicated with
ll down and IB.
SeV (100 HAU/ml) for 24 hr. Cell lysates were immunoprecipitated either with
as analyzed to show expression.
an primary foreskin fibroblasts (HFF) were stimulated with SeV (160 HAU/ml) for
either mock infected or infected with 100 HAU/ml SeV for 8 hr immunostained
te the puntae formation, and insets show magnified puntaes.
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Figure 7. OASL Specifically Enhances RIG-I Signaling by Mimicking pUb to Activate RIG-I
(A) Ubiquitination or p(Ub) binding mutants of RIG-I can be activated in the presence of OASL. Cells were transfected with wild-type (WT) or mutant RIG-I
constructs for 24 hr and analyzed by IB with indicated antibodies.
(B) OASL is capable of promoting RIG-I activation in the absence of TRIM25. Cells were transfected with 50 nMTRIM25 siRNA (Zeng et al., 2010) or control siRNA
for 48 hr followed by SeV infection for 16 hr and IB analysis.
(C) OASL enhances RIG-I(N) oligomerization similar to pUb. 50 or 100 ng of purified RIG-I(N) (GST tagged) were incubated either with K63-linked polyubiquitin
chain (mixture of (pUb) > 3, Boston Biochem) or with purified OASL for 1 hr at 30
C in the binding buffer (20 mM HEPES-KOH [pH 7.4]; 5 mM MgCl2 and 1X
proteinase inhibitor cocktails). The incubated proteins were analyzed by native PAGE followed by IB with anti-GST antibody.
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be quite distinct between mice and humans (Seok et al., 2013).
Specifically, the rodent OAS system is unique, with a total of
12 OAS genes and at least one previously described function
specific to rodents. The mouse Oas1b is critical for resistance
to Flavivirus inmice but a similarmechanism does not exist in hu-
mans (Perelygin et al., 2002). Therefore, this study establishes
the unique antiviral activity of human OASL and provides a
mechanistic basis of its function.
Type I IFNs induce hundreds of genes in different cells collec-
tively known as ISGs. Although the antiviral activities of a large
number of ISGs have been tested against a number of viruses
(Liu et al., 2012; Schoggins et al., 2011, 2014), the biochemical
and cellular basis of the antiviral property for only a handful of
them has been delineated (Sadler and Williams, 2008; Sarkar
and Sen, 2004). Our results therefore demonstrate a unique
mechanism by which an ISG modulates antiviral signaling and
provide important insights into themolecular events thatmediate
the antiviral effects of humanOASL, a commonly expressed ISG.
From a number of biochemical and structural studies (Civril
et al., 2011; Jiang et al., 2011; Kowalinski et al., 2011; Luo
et al., 2011), a model for RIG-I activation has been proposed
as follows. Without RNA, full-length RIG-I adopts an autoinhi-
bited conformation. In this state, intramolecular interactions be-
tween the CARDs and the helicase domain inhibit pUb binding
to the CARDs, while the CTD remains relatively free to bind
50pppRNA. Upon binding to viral RNA through the CTD, the heli-
case domain changes conformation, thereby enabling it to hy-
drolyze ATP and further interact with RNA, thus disrupting the
CARD-helicase interaction (termed the ‘‘competent state’’).
The CARDs then bind to pUb, converting RIG-I to an active
competent state, which is followed by CARD-mediated MAVS
aggregation and signaling (Jiang and Chen, 2012; O’Neill and
Bowie, 2011). Recent observations also suggest RNA-depen-
dent RIG-I aggregation in case of longer RNA to promote
MAVS activation (Patel et al., 2013; Peisley et al., 2013). Although
for larger dsRNA the strict requirement of pUb for RIG-I activa-
tion has been a topic of debate, in most cases RIG-I activation946 Immunity 40, 936–948, June 19, 2014 ª2014 Elsevier Inc.is strongly regulated by a two-stepmechanism requiring simulta-
neous binding of two ligands—RNA and pUb—probably to avoid
aberrant activation of antiviral innate immunity and IFN induction.
Based upon our studies, we propose an additional model of RIG-
I activation (Figure S5E). In this model, OASLwould be present at
very low levels in naive cells. Upon virus infection, RIG-I would be
activated by viral RNA and pUb, resulting in quick induction of
IFN and ISGs like OASL through IRF3. After the initial viral infec-
tion and OASL induction (which is equivalent to our OASL-ex-
pressing cells) in the infected and the surrounding cells through
IFN signaling, OASL will bind to RIG-I and mimic pUb. This will
probably make RIG-I activation more sensitive, requiring just
one ligand, viral RNA, and lead to enhanced IFN induction. The
OASL-bound RIG-I may well represent a distinct intermediate
state of RIG-I, with increased RNA sensitivity and more ready
activation by lower amount of viral RNA.
Our results also demonstrate a unique specificity of human
OASL in enhancing the RIG-I pathway. We found that OASL
did not enhance MDA5 activity, which is supported by our data
showing the inability of OASL to protect from EMCV and
Coxsackievirus B infection (data not shown), which are both de-
tected by MDA5 (Loo and Gale, 2011). Although there has been
no evidence that MDA5 requires ubiquitination for its activation,
recent results suggest that MDA5 also binds pUb, which is
important for its function (Jiang et al., 2012). However, when
we tested the interaction of MDA5 CARDs (MDA5(N)) with
OASL and compared it with that of RIG-I, it was only the RIG-I
CARDs (RIG-I(N)) that interacted with OASL, providing an expla-
nation for the specific nature of OASL-mediated RIG-I activa-
tion. Additionally, OASL also enhanced RIG-I(N) oligomerization
without affecting that for MDA5(N). This demonstrates a highly
specific function of OASL as an alternative ligand and activator
of the RIG-I pathway.
The expression of RIG-I and a number of RIG-I-associated
pathway proteins is generally maintained at low levels and
controlled through IRF3 and/or IFN signaling. Thus, a critical
aspect of host cell defense is to induce potent and rapid antiviral
signaling upon sensing of a virus infection. The rapid induction of
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Antiviral Activity of Human OASLOASL in uninfected cells via IFN signaling could thereby both in-
crease the sensitivity of RIG-I signaling and induce amore potent
antiviral response. Another possible advantage for OASL-medi-
ated RIG-I activation is that the pUb chains can be labile in
the presence of cellular or viral deubiquitinase activity, which
may limit the quantities available for RIG-I activation during the
course of a viral infection. Furthermore, this could serve as an
additional mechanism utilized by the host cell to activate RIG-I
in the absence of pUb as a means to escape viral antagonism.
For example, several viruses directly target RIG-I and/or regula-
tors of RIG-I signaling as a mechanism to attenuate host innate
immune signaling (Bowie and Unterholzner, 2008; Versteeg
and Garcı´a-Sastre, 2010). Of particular interest, a number of
viruses target ubiquitin ligases or encode for deubiquitinases
(DUBs) and DUB-like molecules that function to alter the cellular
ubiquitin machinery in order to facilitate their replication or to
evade host innate immunity. For example, the influenza virus
nonstructural protein NS1 targets TRIM25 to inhibit RIG-I-medi-
ated type I IFN induction (Gack et al., 2009). Thus, the activation
of RIG-I byOASL in the absence of pUbmay provide the host cell
with a critical layer of defense that might serve to escape virus-
mediated antagonism. In summary, we describe a mechanism
by which human OASL, an evolutionary conserved ISG, and its
functional mouse homolog Oasl2 confer an added layer of anti-
viral signal regulation to host cells in order to efficiently combat
viral infections.
EXPERIMENTAL PROCEDURES
Cells, Reagents, Viruses, and Mice
HT1080, HEK293, and 293T cells were cultured in DMEM with 10% FBS and
penicillin/streptomycin; HCT-116 cells were inMcCoy’s 5aMedium (Life Tech-
nologies) with 10% FBS and antibiotics. BMDMs were obtained by differenti-
ating bone marrow cells from 4-week-old Oasl2/ and control WT mice
for 1 week with M-CSF (30 ng/ml)-containing medium as described before.
Low-molecular-weight poly(I:C) was from InvivoGen, and high-molecular-
weight poly(I:C) was from GE Life Science. Fugene 6 and GFP antibody
were purchased from Roche. V5 monoclonal, FITC conjugated anti-rabbit,
and Alexa Fluor 594 conjugated anti-mouse antibodies were from Life Tech-
nologies. FLAG antibody and antibody conjugated beads, OASL shRNA
pLKO.1 constructs were from Sigma-Aldrich. RIG-I antibody was from Cell
Signaling Technology and OASL antibody was from Abgent. ISG56, ISG60,
actin, and Sendai virus C protein antibodies have been described before
(Zhu et al., 2011). Mouse IFN-b ELISA kit was from PBL interferon source. Sen-
dai virus (SeV, Cantell strain) was purchased from Charles River Laboratories.
EMCV (ATCC), EGFP-tagged VSV, and GFP-tagged HSV1 (KOS strain) have
been described before (Zhu et al., 2011). Long strain A serotype RSV has
been described before (Goswami et al., 2013). DENV-2 (16681) was from
BEI Resources and expanded as described (Vasilakis et al., 2008). Oasl2/
mice (strain C57BL/6N) embryos were obtained from International Knockout
Mouse Consortium and rederived at the Jackson Lab, and the control mice
(strain C57BL/6J) were purchased from Jackson Lab. All themice experiments
were carried out according to University of Pittsburgh IACUC guidelines. For
all the experiments representative results are shown from a minimum of three
biological repeats. Wherever applicable, plots show mean with standard error
bars, where closed diamond (A) set as 1 for comparison. Statistical analyses
were carried out with GraphPad Prism. *p < 0.05, **p < 0.01, and NS indicates
not statistically significant by two-tailed Student’s t test analysis.
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